AptarGroup Inc logo

AptarGroup Inc(ATR)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 10 days
PROFIT SINCE LAST BUY
-0.19% ▼
LAST CLOSE
$143.09
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for ATR

11/13/2026: ATR (1-star) has a low Upturn Star Rating. Not recommended to BUY.

AptarGroup Inc is a global supplier of precision dispensing, sealing, and drug delivery systems operating across the pharmaceutical, beauty, and consumer markets. The company's primary strength lies in its high-margin Pharma segment, which features sticky customer relationships and proprietary respiratory and nasal delivery technologies. Its core investment narrative centers on secular healthcare growth and specialized drug delivery innovations, balanced against risks like raw material inflation and valuation sensitivities. The stock suits dividend-conscious and low-risk investors seeking stable industrial-healthcare exposure, with ongoing watch points including pharmaceutical pipeline approvals and raw material cost trends.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitOffers reliable mid-single-digit expansion with upside from pharma innovation, though it lacks hyper-growth tech characteristics.
Momentum investorStrong fit while signal remains positiveSuitable when technical breakouts align with positive earnings surprises and strong pharmaceutical volume updates.
Value investorMixed fitTrades at a moderate premium valuation multiple due to its high-quality pharma franchise and earnings stability.
Dividend investorStrong fitAptarGroup features a dependable dividend payout history with regular annual increases and stable cash flows.
Low-risk investorStrong fitExhibits lower cyclical volatility than traditional commodity packaging companies thanks to its defensive pharmaceutical exposure.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityMediumThe stock experiences moderate price fluctuations driven by broader market shifts and raw material cost reports.
Valuation riskMedium / highShares often command a premium earnings multiple relative to basic packaging peers, leaving little room for earnings misses.
Competition risk (specialized packaging and drug delivery)MediumRival packaging and device manufacturers continuously vie for lucrative pharma and beauty contracts.
Business qualityStrongAptarGroup possesses a high-quality franchise backed by proprietary medical device designs and sticky customer relationships.
Dividend incomeLowDividend payouts are safe and well-covered by cash flows, though the current yield is modest.
Execution riskMediumSuccessful integration of recent medical acquisitions and scaling new pharma devices are crucial for meeting growth targets.

Key Highlights

Company Size Mid-Cap Stock
Market Capitalization 9.07B USD
Price to earnings Ratio 34.56
1Y Target Price 163.88
Price to earnings Ratio 34.56
1Y Target Price 163.88
Volume (30-day avg) 536.4K shares
Beta 0.32
52 Weeks Range 110.17 - 148.11
Updated Date 11/15/2026
52 Weeks Range 110.17 - 148.11
Updated Date 11/15/2026
Dividends yield (FY) 1.35%
Basic EPS (TTM) 4.14

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Medical Instruments & Supplies

BUY participation
60.0%
Active BUY / eligible
3 / 5
30-Day BUY Count Change
+1

Eligible universe: 5 stocks.

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Flat / Range-Bound
PRICE PATH

Flat / Range-Bound

The stock price has been trading within a narrow range with minimal directional movement.

Smooth
PRICE STABILITY

Smooth

The stock has moved along a generally orderly path with only modest fluctuations.

Analysis of Past Performance

Type Stock
Historic Profit -6.21%
Avg. Invested days 40
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
ATR receives a 3-star rating, supported by solid company fundamentals, solid quantitative characteristics, and solid analyst coverage. The rating is constrained by weak price momentum.

Company Fundamentals

★★★★★
ATR has solid overall fundamentals (4 stars), with moderate financial health, moderate growth momentum, and solid ownership. In FY2025 versus FY2024, moderate earnings growth (+4.9%) and solid cash generation (FCF margin 7.9%) are partially offset by moderate revenue growth (+5.4%), modest insider ownership of 1.67%.

Financial Health Rating

★★★★★
ATR's financial health is supported by solid cash strength, including free-cash-flow generation (7.9% of revenue). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Revenue growth is ATR's strongest growth driver at +5.4% FY2025 versus FY2024 (moderate, 3 stars). By comparison, while free-cash-flow growth (-14.2%, negative) holds the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 98.7% and approximately 99.0% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.67% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 9.68%
State Farm Mutual Automobile Ins Co 7.48%
Vanguard Portfolio Management, LLC 5.74%
Morgan Stanley - Brokerage Accounts 5.56%
Vanguard Capital Management, LLC 4.57%

Unit Economics (Per $1K Revenue)

★★★★★
ATR generates approximately $296 of gross profit, $136 of operating income, and $79 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Soft margins and soft cash conversion support a 3-star rating, while capital efficiency is moderate.

Economic Dimensions

★★★★★
Effective Tax Rate: 20.12%

Quantitative Style Profile

★★★★★
ATR has a liquid, relatively low-volatility profile. Weak momentum is the primary drawback, while valuation that is moderately attractive rather than deeply discounted.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
PharmaNasal spray pumps, metered-dose inhaler valves, ophthalmic dispensers, and injectable components.This is the company's profit engine, generating high margins from essential prescription and consumer healthcare drug delivery systems.
BeautyFine mist sprayers, lotion pumps, airless systems, and cosmetic closures.Provides steady cash flow tied to global prestige and mass cosmetics, fragrance, and skincare brand demands.
ClosuresDispensing and non-dispensing caps for food, beverage, home care, and personal care packaging.Offers high-volume baseline revenue linked to everyday consumer staples and household goods.
Geography (Europe, North America, Asia)Global manufacturing footprint spanning Europe, the United States, China, and other international markets.Geographic diversification helps insulate the business from localized economic downturns.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2026-10-29
When After Market
Estimate 1.46
Actual 1.52

Profitability

Profit Margin 6.7%
Operating Margin (TTM) 12.38%

Management Effectiveness

Return on Assets (TTM) 6.05%
Return on Equity (TTM) 9.79%

Valuation

Trailing PE 34.56
Forward PE 23.58
Enterprise Value 10.28B
Price to Sales(TTM) 2.27
Enterprise Value 10.28B
Price to Sales(TTM) 2.27
Enterprise Value to Revenue 2.57
Enterprise Value to EBITDA 14
Shares Outstanding 63.39M
Shares Floating 62.78M
Shares Outstanding 63.39M
Shares Floating 62.78M
Percent Insiders 1.67
Percent Institutions 98.65

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.